Here’s a glimmer of hope in the fight against Zika. Inovio Pharmaceuticals, Inc. and GeneOne Life Science, Inc. announced they have received authorization to introduce an initial phase of a human trial to evaluate the Inovio Zika DNA vaccine to prevent infection from the virus. In preclinical testing the synthetic vaccine induced robust antibody and T cell responses in small and large animal models. This shows the product’s potential to prevent infection from this harmful pathogen in humans.
The first phase, with an open-label, dose-ranging study with 40 healthy subjects will evaluate the safety, tolerability of the vaccine administered with Cellectra.
Inovio’s President and CEO announced they have received approval to initiate the first Zika vaccine study in human volunteers. They plan to dose their first subjects in the next weeks and report phase I interim results later this year.
GeneOne Life is pleased to help move this Zika vaccine through the clinical and regulatory process and conducting the trial to help combat this dreaded virus.
We want to help keep you and your loved ones safe against Zika as well! Our barrier treatment guarantees you an 85-90% reduction in mosquitoes while staying on a 21 day treatment schedule. We have great packages available to get you the coverage you need to last through September. Let’s all help fight the bite against Zika!